Atrial Fibrillation (AFib) is a common type of cardiac arrythmia that affects millions of Americans and is a major risk factor for the fifth leading cause of death in the U.S. — stroke.

While recent advancements in implantable and wearable technologies provide a number of methods for clinicians to screen for AFib, more questions about surveillance and treatment have arisen. Who needs to be monitored and for how long? Which patients require implantable devices vs. which can continue to be monitored using wearable health devices? Who warrants anticoagulation therapy or other interventions, such as ablation?

With these innovative technologies increasing in affordability and becoming more accessible, the ACC recognizes that now is the perfect time to bring together a diverse group of experts to start addressing some of these issues. The Ongoing Dilemmas with Surveillance and Diagnosis of Atrial Fibrillation virtual Heart House Roundtable will serve as a valuable forum to delve deep into these critical issues. Through interactive discussions, participants will address clinical care gaps regarding the surveillance, diagnosis, and treatment of AFib particularly in patients post-cryptogenic stroke as well as in subclinical AF of shorter duration or lower burden.